T. Rowe Price Associates
AXDX

T. Rowe Price Associates’s Accelerate Diagnostics AXDX Stock Holding History

T. Rowe Price Associates’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,390
Closed -$52K – 2895
2023
Q2 		$52K Hold
6,390
– – ﹤0.01% 2797
2023
Q1 		$45K Sell
6,390
-2,638
-29% -$15.9K ﹤0.01% 2801
2022
Q4 		$64K Hold
9,028
– – ﹤0.01% 2781
2022
Q3 		$138K Hold
9,028
– – ﹤0.01% 2652
2022
Q2 		$90K Buy
9,028
+4,573
+103% +$40.4K ﹤0.01% 2775
2022
Q1 		$64K Buy
4,455
+2,620
+143% +$74.6K ﹤0.01% 2899
2021
Q4 		$96K Buy
1,835
+320
+21% +$17.8K ﹤0.01% 2881
2021
Q3 		$88K Buy
1,515
+30
+2% +$1.96K ﹤0.01% 2861
2021
Q2 		$120K Buy
+1,485
New +$118K ﹤0.01% 2819
2018
Q4 		– Sell
-958
Closed -$220K – 2564
2018
Q3 		$220K Buy
958
+36
+4% +$7.96K ﹤0.01% 2441
2018
Q2 		$206K Buy
922
+3
+0.3% +$671 ﹤0.01% 2449
2018
Q1 		$210K Buy
919
+8
+0.9% +$2.1K ﹤0.01% 2400
2017
Q4 		$239K Sell
911
-46
-5% -$10.8K ﹤0.01% 2360
2017
Q3 		$215K Buy
+957
New +$235K ﹤0.01% 2391

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $139M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates's AXDX Position: Q3 2023 in Review

T. Rowe Price Associates sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 6,390 shares — an estimated $52K sold.

T. Rowe Price Associates first reported a position in AXDX in Q3 2017 and held it in 14 quarters. The position peaked at $239K in Q4 2017. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

  • T. Rowe Price Associates reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 6,390 Accelerate Diagnostics shares in Q3 2023, an estimated $52K.
  • T. Rowe Price Associates first reported a position in Accelerate Diagnostics in Q3 2017 and held it in 14 quarters.
  • T. Rowe Price Associates's Accelerate Diagnostics position peaked at $239K in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.